Summit Therapeutics says its cash won’t cover operations for a year, raising going-concern concerns. Shares fall as the company seeks funding while advancing ivonescimab development.
Bernstein remains bearish on Summit, citing doubts about trial success and expecting weak results ahead.
Analysts warn Summit may fail key trials, lacks revenue, and faces pressure—raising doubts about its future and stock upside.
Summit stock fell after its cancer drug update was just “keep going,” not the big win investors hoped for.
Stifel rates Summit Therapeutics a Buy. Its new cancer drug looks promising, and strong trial results could send the stock much higher.
Summit Therapeutics' promising lung cancer drug, ivonescimab, shows great results in China but struggles in Western trials, raising questions about its global future and impact on biotech.
